IDEXX Laboratories (IDXX) Receives Daily Coverage Optimism Score of 0.15
Media headlines about IDEXX Laboratories (NASDAQ:IDXX) have been trending somewhat positive on Thursday, Accern Sentiment reports. Accern scores the sentiment of press coverage by analyzing more than 20 million news and blog sources. Accern ranks coverage of publicly-traded companies on a scale of negative one to one, with scores nearest to one being the most favorable. IDEXX Laboratories earned a news sentiment score of 0.15 on Accern’s scale. Accern also assigned news headlines about the company an impact score of 46.0757950830364 out of 100, indicating that recent press coverage is somewhat unlikely to have an impact on the company’s share price in the next few days.
Here are some of the news headlines that may have effected Accern Sentiment Analysis’s analysis:
- Cramer’s lightning round: This is your chance to get into ‘up stock’ Idexx Labs – CNBC (cnbc.com)
- 4 Top Growth Picks to Avoid Tax Tangle in MedTech (finance.yahoo.com)
- Td Asset Management Inc Sells A Little More Idexx Laboratories (IDXX) Stock – First News 24 (firstnewspaper24.com)
- ETFs with exposure to IDEXX Laboratories, Inc. : November 13, 2017 (finance.yahoo.com)
IDEXX Laboratories (NASDAQ:IDXX) traded up $1.86 during mid-day trading on Thursday, hitting $151.40. 660,500 shares of the company’s stock traded hands, compared to its average volume of 713,562. The stock has a market capitalization of $13,420.00, a price-to-earnings ratio of 50.35, a price-to-earnings-growth ratio of 2.26 and a beta of 0.46. IDEXX Laboratories has a 1-year low of $112.41 and a 1-year high of $173.01. The company has a current ratio of 0.95, a quick ratio of 0.77 and a debt-to-equity ratio of -12.48.
IDEXX Laboratories (NASDAQ:IDXX) last released its quarterly earnings results on Tuesday, October 31st. The company reported $0.79 EPS for the quarter, beating the Thomson Reuters’ consensus estimate of $0.74 by $0.05. The firm had revenue of $492.00 million for the quarter, compared to analysts’ expectations of $492.94 million. The business’s quarterly revenue was up 9.7% compared to the same quarter last year. During the same period in the previous year, the company posted $0.62 earnings per share. sell-side analysts expect that IDEXX Laboratories will post 3.24 EPS for the current year.
A number of analysts recently weighed in on the stock. BidaskClub lowered shares of IDEXX Laboratories from a “buy” rating to a “hold” rating in a research note on Monday, July 31st. Zacks Investment Research raised shares of IDEXX Laboratories from a “hold” rating to a “buy” rating and set a $186.00 price objective for the company in a research note on Wednesday, July 19th. Stifel Nicolaus reaffirmed a “buy” rating and issued a $185.00 price objective on shares of IDEXX Laboratories in a research note on Tuesday, October 24th. CL King raised shares of IDEXX Laboratories from a “neutral” rating to a “buy” rating and set a $200.00 price objective for the company in a research note on Friday, July 28th. Finally, Canaccord Genuity reaffirmed a “buy” rating and issued a $180.00 price objective on shares of IDEXX Laboratories in a research note on Friday, October 6th. Two research analysts have rated the stock with a sell rating, one has issued a hold rating and five have issued a buy rating to the company’s stock. The stock presently has a consensus rating of “Hold” and an average price target of $173.67.
In other IDEXX Laboratories news, Director Rebecca M. Henderson sold 5,156 shares of the stock in a transaction dated Wednesday, August 23rd. The shares were sold at an average price of $153.29, for a total transaction of $790,363.24. Following the completion of the sale, the director now directly owns 17,274 shares of the company’s stock, valued at $2,647,931.46. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. Also, Director Rebecca M. Henderson sold 2,578 shares of the stock in a transaction dated Tuesday, August 22nd. The shares were sold at an average price of $152.86, for a total transaction of $394,073.08. Following the sale, the director now directly owns 17,274 shares of the company’s stock, valued at $2,640,503.64. The disclosure for this sale can be found here. Over the last three months, insiders have sold 92,734 shares of company stock valued at $14,083,486. Insiders own 2.77% of the company’s stock.
IDEXX Laboratories Company Profile
IDEXX Laboratories, Inc develops, manufactures and distributes products and provides services for the companion animal veterinary, livestock and poultry, dairy and water testing markets. The Company also sells a line of portable electrolytes and blood gas analyzers for the human point-of-care medical diagnostics market.
Receive News & Ratings for IDEXX Laboratories Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for IDEXX Laboratories Inc. and related companies with MarketBeat.com's FREE daily email newsletter.